Mylab and Hemex launch new COVID-19 test

LabPulse.com staff writers
Jul 6, 2022
2020 05 05 20 17 1261 Sars Co V 2 Antibodies 400

Mylab Discovery Solutions of India and Portland, OR-based Hemex Health have launched the Gazelle PathoCatch COVID-19 fluorescent immunoassay.

The lateral flow test is the result of a collaborative effort to develop COVID-19 point-of-care testing in India.

According to the companies, it is portable, lightweight, and detects all COVID-19 variants in 20 seconds with 99.4 percent accuracy compared to polymerase chain reaction (PCR) tests.

The diagnostic test is currently under review by the U.S. Food and Drug Administration (FDA) for emergency use authorization and will launch in Africa and the Middle East later this summer, the companies said.

In its report "In Vitro Diagnostics (IVD) in India," Kalorama Information, a sister publication of LabPulse.com, recently said that the country's IVD market has reached $1 per person, up from $.58 per person in 2016.

Latest in Emergency Use Authorization
Coronavirus Covid Blue Social
FDA awards EUA to Alphadera Labs’ COVID-19 test
August 2, 2023
Fda Button Social
FDA authorizes Discover Labs to run molecular COVID-19 test at its Texas facility
July 7, 2023
At-home or Lab-based STI testing/collection
Sponsored
At-home or Lab-based STI testing/collection
September 6, 2023
Covid Test Preschool Social
Mologic receives FDA EUA for at-home SARS-CoV-2 antigen test, eyes additional respiratory diseases
February 27, 2023
Related Stories
2021 08 18 22 53 0531 Covid 19 Self Swab Test 400
Health Topics
Color Health, CDC to increase access to COVID-19 testing
2020 05 05 21 16 5661 Coronavirus Global Spread 400
Infectious
Lateral flow tests miss significant number of COVID infections
2020 06 15 18 14 5259 Swab Sample Collection 400
Health Topics
MaximBio gets EUA for ClearDetect COVID-19 home test
At-home or Lab-based STI testing/collection
Sponsor Content
At-home or Lab-based STI testing/collection
More in Emergency Use Authorization
FDA awards EUA to Alphadera Labs’ COVID-19 test
Alphadera Labs received the EUA after evaluating its test on 60 clinical nasopharyngeal swabs specimens. ALPHADx provided the same results as a “highly sensitive” FDA-authorized molecular SARS-CoV-2 test.
August 2, 2023
Coronavirus Covid Blue Social
FDA authorizes Discover Labs to run molecular COVID-19 test at its Texas facility
Under the terms of the EUA, Discover Labs can run the COVID-19 test at its CLIA-certified Austin facility. The test is for prescription use only.
July 7, 2023
Fda Button Social
Cue Health receives FDA emergency use authorization for molecular mpox test
The test demonstrated high accuracy in clinical trials, achieving 100% concordance with the Center for Disease Control and Prevention’s (CDC's) mpox test on the samples tested, Cue Health said.
March 20, 2023
Monkeypox Virus Social
Mologic receives FDA EUA for at-home SARS-CoV-2 antigen test, eyes additional respiratory diseases
The development of the rapid antigen test was funded under an $11.8 million contract through the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative.
February 27, 2023
Covid Test Preschool Social
Lucira Health files for bankruptcy despite receiving FDA green light
The firm is seeking a strategic or financial partner for the resumption of manufacturing and development of additional home diagnostic testing products.
February 27, 2023
Business Deal Corporate Social
FDA authorizes Lucira Health OTC test, the first to detect influenza and COVID-19 viruses
In people with symptoms, the Lucira COVID-19 & Flu Test correctly identified 99.3% of negative and 90.1% of positive influenza A samples; 100% of negative and 88.3% of positive COVID-19 samples; and 99.9% of negative influenza B samples, the FDA said.
February 24, 2023
Fda Button Social
FDA grants emergency use authorization for Anavasi LAMP-based COVID-19 test, detector
Anavasi said its point-of-care platform will enable the rapid development of tests to detect viral and bacterial targets, including influenza, respiratory syncytial virus (RSV), and sexual health-related strains, among others.
February 13, 2023
Virus Coronavirus Covid 19 Social
FDA authorizes Cepheid molecular test to detect monkeypox virus at the point of care
The Xpert Mpox test is a real-time polymerase chain reaction assay to detect Mpox virus DNA in lesion swab specimens from individuals suspected of monkeypox by their healthcare provider.
February 10, 2023
3 D Monkeypox Infecting Cell Social
BD nabs FDA authorization for SARS-CoV-2, influenza A/B, RSV combination test
The test uses a single nasal or nasopharyngeal swab sample to identify and distinguish whether a patient has COVID-19, the flu, RSV, or some combination of the three, with results available in two hours.
February 8, 2023
Quality Check Mark Social
LumiraDx obtains FDA authorization for test to detect flu A, flu B, SARS-CoV-2
The test leverages a single-step direct method for nucleic acid extraction and amplification on validated open RT-PCR instruments.
February 7, 2023
Covid 19 Antibody Social
Lucira Health applies for FDA Emergency Use Authorization of over-the-counter COVID-19, flu A, flu B molecular test
The single-use test fits in the palm of the hand, runs on two AA batteries, and with one shallow nasal swab provides a positive or negative result for COVID-19, flu A, or flu B in less than 30 minutes.
January 3, 2023
Sars Co V 2 Covid 19 Mask Pixabay Social
Visby Medical receives FDA Emergency Use Authorization for respiratory test in CLIA-waived settings
The Respiratory Health Test is a rapid PCR device that detects and differentiates upper respiratory infections caused by influenza A & B and SARS-CoV-2.
January 3, 2023
Fda Button Social
Page 1 of 14
Next Page